Cellect Biotechnology logo

APOP - Cellect Biotechnology News Story

$2.74 0.0  0.4%

Last Trade - 15/01/21

Sector
Healthcare
Size
Micro Cap
Market Cap £4.60m
Enterprise Value £84.6k
Revenue £n/a
Position in Universe 6086th / 6547

BRIEF-Cellect Biotechnology's Apograft To Empower Cellular Treatment Of Covid-19 Related Pulmonary Diseases

Mon 18th May, 2020 1:17pm
May 18 (Reuters) - Cellect Biotechnology Ltd  APOP.O :
    * CELLECT BIOTECHNOLOGY'S APOGRAFT™ TO EMPOWER CELLULAR
TREATMENT
OF COVID-19 RELATED PULMONARY DISEASES
    * CELLECT BIOTECHNOLOGY - CLINICAL RESULTS IN GVHD STUDIES
MAY BE
BENEFICIAL IN COVID-19 AND CAR-T CYTOKINE STORM MANIFESTATIONS
    * CELLECT BIOTECHNOLOGY - SIGNED A DEVELOPMENT AGREEMENT
WITH
CONSORTIUM TO EXAMINE THERAPEUTIC EFFECTS OF APOGRAFT TREATED
STEM CELLS
    * CELLECT BIOTECHNOLOGY LTD - DEVELOPMENT AGREEMENT INCLUDES
A
COMMERCIAL COMPONENT
    * CELLECT BIOTECHNOLOGY LTD - DID NOT DISCLOSE TERMS OF
AGREEMENT,
NOR ANY MEMBERS OF INTERNATIONAL CONSORTIUM

Source text for Eikon:  ID:nPn9w1KgGa 
Further company coverage:  APOP.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.